Elevated cholesteryl ester transfer protein concentration is associated with an increased risk for cardiovascular disease in women, but not in men, with Type 2 diabetes: the Hoorn Study

Aims  Cholesteryl ester transfer protein (CETP) exchanges neutral lipids between lipoproteins. As the role of CETP in the atherogenic process is still not fully clarified, we studied the association of CETP concentration with the prevalence of cardiovascular disease (CVD) and with intima‐media thickness of the carotid artery (IMT) in subjects with normal glucose tolerance (NGT), impaird fasting glucose and/or impaired glucose tolerance (IFG/IGT) and Type 2 diabetes mellitus.

[1]  A. V. van Roon,et al.  Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. , 2005, Diabetes.

[2]  L. Bouter,et al.  Metabolic Syndrome and 10-Year Cardiovascular Disease Risk in the Hoorn Study , 2005, Circulation.

[3]  H. Ginsberg,et al.  Regulation of plasma triglycerides in insulin resistance and diabetes. , 2005, Archives of medical research.

[4]  S. Hammami,et al.  Association of plasma cholesteryl ester transfer protein activity and polymorphism with coronary artery disease extent in Tunisian type II diabetic patients. , 2005, Clinical biochemistry.

[5]  P J Talmud,et al.  Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment: Individual Patient Meta-Analysis of 13 677 Subjects , 2005, Circulation.

[6]  M. Castro Cabezas,et al.  Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis. , 2005, Atherosclerosis.

[7]  J. Kastelein,et al.  A review of CETP and its relation to atherosclerosis Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.R400007-JLR200 , 2004, Journal of Lipid Research.

[8]  R. Peters,et al.  Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)–Norfolk Population Study , 2004, Circulation.

[9]  R. Marfella,et al.  Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus , 2004, Circulation.

[10]  A. Zwinderman,et al.  The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. , 2004, Atherosclerosis.

[11]  L. Bouter,et al.  The relationship of lipoprotein lipase activity and LDL size is dependent on glucose metabolism in an elderly population: the Hoorn Study. , 2004, Diabetes care.

[12]  A. Zwinderman,et al.  Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS) , 2004, European journal of clinical investigation.

[13]  L. Bouter,et al.  Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study , 1996, Diabetologia.

[14]  L. Bouter,et al.  Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. , 2003, European heart journal.

[15]  J. Kastelein.  The future of lipid-lowering therapy: the big picture. , 2003, The Netherlands journal of medicine.

[16]  N. Westerhof,et al.  Arterial Stiffness Increases With Deteriorating Glucose Tolerance Status: The Hoorn Study , 2003, Circulation.

[17]  D. Rader,et al.  Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[18]  A. Zwinderman,et al.  Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-->A polymorphism and a novel promoter variant are independently associated with CETP concentration. , 2003, Human molecular genetics.

[19]  L. Bouter,et al.  Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. , 2002, Diabetes care.

[20]  S. Vega-López,et al.  Pre-Menopausal Women, Classified as Hypo- or Hyper-Responders, do not Alter their LDL/HDL Ratio Following a High Dietary Cholesterol Challenge , 2002, Journal of the American College of Nutrition.

[21]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[22]  A. Algra,et al.  Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. , 2001, Atherosclerosis.

[23]  A. van Tol,et al.  Proatherogenic Role of Elevated CE Transfer From HDL to VLDL1 and Dense LDL in Type 2 Diabetes: Impact of the Degree of Triglyceridemia , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[24]  M. Gibney,et al.  Effect of postprandial lipaemia and Taq 1B polymorphism of the cholesteryl ester transfer protein (CETP) gene on CETP mass, activity, associated lipoproteins and plasma lipids , 2000, British Journal of Nutrition.

[25]  P. Barter,et al.  Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. , 1998, Atherosclerosis.

[26]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[27]  J W Jukema,et al.  The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. , 1998, The New England journal of medicine.

[28]  R. Heine,et al.  Measurement of low-density lipoprotein particle size by high-performance gel-filtration chromatography. , 1997, Clinical chemistry.

[29]  D Kromhout,et al.  The Dutch EPIC food frequency questionnaire. I. Description of the questionnaire, and relative validity and reproducibility for food groups. , 1997, International journal of epidemiology.

[30]  J A Kors,et al.  Validation of a new computer program for Minnesota coding. , 1996, Journal of electrocardiology.

[31]  S. Grundy,et al.  Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[32]  G. Ponsin,et al.  Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. , 1993, Atherosclerosis.

[33]  A. Tall,et al.  Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[34]  F. Dunn,et al.  Hyperlipidemia in diabetes mellitus. , 1990, Diabetes/metabolism reviews.

[35]  D. B. Zilversmit,et al.  Inter-relationship of lipids transferred by the lipid-transfer protein isolated from human lipoprotein-deficient plasma. , 1983, The Journal of biological chemistry.

[36]  Ronald J. Prineas,et al.  The Minnesota code manual of electrocardiographic findings : standards and procedures for measurement and classification , 1982 .

[37]  H. Blackburn,et al.  Cardiovascular survey methods. , 1969, Monograph series. World Health Organization.

[38]  A. Tall,et al.  Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.